[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07335510":3,"trial-entities:NCT07335510":255,"trial-summary:NCT07335510":259},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":28,"primary_purpose":29,"phases":30,"enrollment_info":32,"interventions":35,"primary_outcomes":42,"secondary_outcomes":47,"sex":104,"minimum_age":105,"maximum_age":106,"healthy_volunteers":15,"eligibility_criteria":107,"std_ages":134,"locations":137,"central_contacts":236,"overall_officials":241,"references":243,"see_also_links":251},"NCT07335510","AAAV9622","Impact of Barostimulation on Hemodynamics in Adults With Heart Failure","Impact of Barostimulation in Cardiac Hemodynamics and Clinical Outcomes Through Use of the Barostim™ CVRx Device","RECRUITING","2028-03","2026-06","2026-06-29","2026-03-30","Columbia University","OTHER",false,"This study evaluates the effects of the implantation and adjustment of the CVRx Barostim device in adult patients with heart failure with reduced ejection fraction who are receiving maximally tolerated doses of guideline directed medical and device therapies. The study aims to assess how therapy using this device affects heart function, symptoms, and exercise capacity, with particular focus on how the device affects blood flow and heart pressures during exercise. Information from this study may help inform patient selection and device management in patients with heart failure.","Heart failure with reduced ejection fraction (HFrEF) remains a major public health concern, associated with high rates of morbidity, hospitalizations, and mortality. Despite advances in medication, as well as device therapies such as implantable devices, a significant proportion of patients continue to experience debilitating symptoms, exercise intolerance, and reduced quality of life.\n\nAn important feature of HFrEF is autonomic imbalance, which contributes to disease progression and adverse outcomes. While current therapies indirectly try to affect this imbalance, the Barostim™ device (CVRx) is the first to specifically target the autonomic nervous system in this population. This device offers a novel mechanistic approach by directly stimulating the carotid baroreceptors to reduce sympathetic activity and restore autonomic balance. This prospective, multicenter study aims to evaluate the effects of the Barostim device on invasive hemodynamics through right heart catheterization (RHC), exercise capacity, and tolerance to medical therapy in HFrEF patients who remain symptomatic despite maximal guideline-directed medical therapy (GDMT). The study seeks to address key knowledge gaps in the mechanistic and clinical response to baroreflex activation therapy (BAT) and inform future integration of this therapy into standard heart failure care.",[19],"HFrEF - Heart Failure With Reduced Ejection Fraction",[21,22,23,24,25,26,27],"Baroreflex activation therapy","Exercise hemodynamics","Barostim","Cardiopulmonary exercise testing","Neuromodulation","Functional capacity","Heart failure with reduced ejection fraction","INTERVENTIONAL","TREATMENT",[31],"NA",{"count":33,"type":34},58,"ESTIMATED",[36],{"type":37,"name":38,"description":39,"armGroupLabels":40},"DEVICE","Baroreflex Activation Therapy","Barostim™ device (CVRx Inc.), a commercially available, FDA-approved device for autonomic modulation in HFrEF. The device system includes an implantable pulse generator, carotid sinus lead, and programmer system. No investigational modifications will be made. The device will be implanted per standard labeling and programming guidelines, and therapy titration will follow manufacturer recommendations.",[41],"Barostim™ Therapy",[43],{"measure":44,"description":45,"timeFrame":46},"Change in peak exercise PCWP at 6 months post-titration","Exercise pulmonary capillary wedge pressure (PCWP) will be measured at peak exercise at approximately six months post-Barostim titration and compared with peak exercise PCWP measured during the pre-implantation phase. Change from baseline will be calculated.","Pre-implantation phase (baseline, 0-2 months) and post-titration phase (approximately 6 months after completion of device titration, i.e. approx. 7-9 months post-implantation).",[48,51,54,57,60,63,66,70,73,76,79,82,85,88,91,94,97,100],{"measure":49,"description":50,"timeFrame":46},"Change in peak exercise load-adjusted PCWP at 6 months post-titration","Exercise pulmonary capillary wedge pressure (PCWP) will be measured at peak exercise at approximately six months post-Barostim titration and compared with peak exercise PCWP measured during the pre-implantation phase. PCWP measurements will be normalized to maximal exercise load at each time point. Change from baseline will be calculated.",{"measure":52,"description":53,"timeFrame":46},"Change in peak exercise output-adjusted PCWP at 6 months post-titration","Exercise pulmonary capillary wedge pressure (PCWP) will be measured at peak exercise at approximately six months post-Barostim titration and compared with peak exercise PCWP measured during the pre-implantation phase. PCWP measurements will be normalized to cardiac output at each time point. Change from baseline will be calculated.",{"measure":55,"description":56,"timeFrame":46},"Change in peak exercise cardiac output at 6 months post-titration","Exercise cardiac output (CO) will be measured at peak exercise at approximately six months post-Barostim titration and compared with peak exercise CO measured during the pre-implantation phase. Change from baseline will be calculated.",{"measure":58,"description":59,"timeFrame":46},"Proportion of participants with significant reduction in PCWP at 6 months post-titration","Exercise pulmonary capillary wedge pressure (PCWP) will be measured at peak exercise at approximately six months post-Barostim titration and compared with peak exercise PCWP measured during the pre-implantation phase. Patients will be categorized into \"responders\" who demonstrate either a 10% reduction in PCWP or a 3 mmHg reduction in PCWP or \"non-responders\" who do not demonstrate at least this degree of percent or absolute change. The proportion of participants that are considered \"responders\" by this metric will be collected and assessed.",{"measure":61,"description":62,"timeFrame":46},"Change in peak exercise mean PA pressures at 6 months post-titration","Exercise mean pulmonary arterial pressure (PAP) will be measured at peak exercise at approximately six months post-Barostim titration and compared with peak exercise mean PAP measured during the pre-implantation phase. Change from baseline will be calculated.",{"measure":64,"description":65,"timeFrame":46},"Change in peak VO2 at 6 months post-titration","Exercise peak VO2 will be measured via cardiopulmonary exercise testing (CPET) at approximately six months post-Barostim titration and compared with peak VO2 measured via CPET during the pre-implantation phase. Change from baseline will be calculated.",{"measure":67,"description":68,"timeFrame":69},"Change in average daily step count","Average daily step counts will be measured via study-provided Fitbit Inspire 3 fitness trackers. Absolute change and trends will be assessed from baseline to monthly time points in the post-implantation phase.","Pre-implantation phase (baseline, 0-2 months) and post-implantation phase monthly (approximately 0-9 months post-implantation).",{"measure":71,"description":72,"timeFrame":46},"Change in average daily step count at 6 months post-titration","The most recent 30-day period of daily step counts will be measured via study-provided Fitbit Inspire 3 fitness trackers and evaluated for the average daily step count. This will be assessed at approximately six months post-Barostim titration and compared with the average of the last 30-day period of daily step counts prior to the end of the pre-implantation phase. Change from baseline will be calculated.",{"measure":74,"description":75,"timeFrame":46},"Change in highest daily step count at 6 months post-titration","The most recent 30-day period of daily step counts will be measured via study-provided Fitbit Inspire 3 fitness trackers and evaluated for the maximum daily step count. This will be assessed at approximately six months post-Barostim titration and compared with the maximum of the last 30-day period of daily step counts prior to the end of the pre-implantation phase. Change from baseline will be calculated.",{"measure":77,"description":78,"timeFrame":46},"Change in estimated peak VO2 at 6 months post-titration","The most recent Fitbit cardio fitness score (estimated peak VO2) will be measured via study-provided Fitbit Inspire 3 fitness trackers. This will be assessed at approximately six months post-Barostim titration and compared with the most recent Fitbit cardio fitness score prior to the end of the pre-implantation phase. Change from baseline will be calculated.",{"measure":80,"description":81,"timeFrame":46},"Change in heart rate variability at 6 months post-titration","The most recent 30-day average of heart rate variability will be measured via study-provided Fitbit Inspire 3 fitness trackers. This will be assessed at approximately six months post-Barostim titration and compared with the average of the last 30-day period prior to the end of the pre-implantation phase. Change from baseline will be calculated.",{"measure":83,"description":84,"timeFrame":46},"Change in proportion of exercise days per month at 6 months post-titration","The most recent 30-day proportion of exercise days will be measured via study-provided Fitbit Inspire 3 fitness trackers. This will be assessed at approximately six months post-Barostim titration and compared with the proportion of exercise days of the last 30-day period prior to the end of the pre-implantation phase. Change from baseline will be calculated.",{"measure":86,"description":87,"timeFrame":46},"Change in six-minute walk test at 6 months post-titration","A six-minute walk test (6MWT) will be performed, and distances will be measured. This will be assessed at approximately six months post-Barostim titration and compared with the 6MWT performed during the pre-implantation phase. Change from baseline will be calculated.",{"measure":89,"description":90,"timeFrame":46},"Change in Kansas City Cardiomyopathy Questionnaire (KCCQ)-12 at 6 months post-titration","The KCCQ in its 12-question version will be performed to assess quality of life, and each question has 5-7 Likert-style response options. Responses are grouped according to domain for domain-specific scores. Overall and domain-specific scores are transformed and standardized and final scores are reported from 0-100, where higher scores reflect less functional limitation and better quality of life (better outcome). This will be assessed at approximately six months post-Barostim titration and compared with the KCCQ scores obtained during the pre-implantation phase. Change from baseline will be calculated.",{"measure":92,"description":93,"timeFrame":46},"Change in heart failure medication score at 6 months post-titration","A heart failure medication score (0-9 points) will be calculated based upon participants' current heart failure medications, with 9 indicating a better outcome. Scored are allocated in the following manner: 2 points for being on a mineralocorticoid receptor antagonist or a sodium-glucose cotransporter 2 inhibitor; 2 points for being on a heart failure-specific beta blocker (carvedilol, metoprolol succinate, or bisoprolol; 2 points for \\>= 50% max guideline-directed dose, 1 point for \\\u003C50% dose, 0 points if not); and 3 points for being on a renin-angiotensin-aldosterone system inhibitor (3 points for an angiotensin receptor-neprilysin inhibitor, or 1-2 points for either an angiotensin-converting-enzyme inhibitor or an angiotensin receptor blocker at \\\u003C50% or \\>=50% max guideline-directed dose). This will be assessed at approximately six months post-Barostim titration and compared with the medication scores obtained during the pre-implantation phase. Change from baseline will be calculated.",{"measure":95,"description":96,"timeFrame":46},"Change in N-terminal prohormone of brain natriuretic peptide at 6 months post-titration","Participants' levels of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) will be obtained via blood draw. This will be assessed at approximately six months post-Barostim titration and compared with the NT-proBNP levels obtained during the pre-implantation phase. Change from baseline will be calculated.",{"measure":98,"description":99,"timeFrame":46},"Change in sleep score at 6 months post-titration","The most recent 30-day average of sleep scores will be measured via study-provided Fitbit Inspire 3 fitness trackers. This sleep score is calculated by Fitbit as a proprietary algorithm to assess sleep quality based upon time asleep, time in sleep stages, movement during sleep, and sleeping heart rate, derived from measurements obtained by the fitness tracker. It is a score graded from 0-100, with 100 being the best score. This will be assessed at approximately six months post-Barostim titration and compared with the proportion of exercise days of the last 30-day period prior to the end of the pre-implantation phase. Change from baseline will be calculated.",{"measure":101,"description":102,"timeFrame":103},"Change in heart failure admissions at 6 months post-titration","Participants' heart failure-related hospital admission counts will be obtained for the preceding six months at each time point. This will be calculated at approximately six months post-Barostim titration and compared with the same calculation of admissions at the time of study intake. Change from baseline will be calculated.","Pre-implantation phase (baseline, approximately 0 months) and post-titration phase (approximately 6 months after completion of device titration, i.e. approx. 7-9 months post-implantation).","ALL","18 Years",null,{"inclusion":108,"exclusion":114,"raw_text":133},[109,110,111,112,113],"Diagnosis of heart failure with reduced ejection fraction (defined as ejection fraction ≤ 35% for the purposes of this study) (should be within 12 months of screen)","Symptoms consistent with one of:","Laboratories with last N-terminal pro-B-type natriuretic peptide (NT-proBNP) \\\u003C 1600 pg\u002Fml (should be within 3 months of screen)","Management with maximally-tolerated GDMT medications and devices","Age \\>= 18 years",[115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132],"Age \\\u003C 18 years","Myocardial infarction (MI), syncope, cerebrovascular accident (CVA), aborted sudden cardiac death (SCD) (and implantable cardioverter defibrillator (ICD) therapy) within 3 months of screening","Bilateral carotid bifurcations located above the level of the mandible","Carotid artery stenosis greater than 50% caused by atherosclerosis","Ulcerative plaques in the carotid artery","Baroreflex failure or autonomic neuropathy","Symptomatic un-controlled bradyarrhythmias","Severe chronic lung disease","Current treatment with inotropes","Pacemaker or ICD within 3 months of screening","Cardiac resynchronization therapy (CRT) devices within 6 months of screening or anticipated to be placed in the next 90 days following screening","Prior surgery, radiation, endovascular stent in the carotid sinus","History or consideration of solid organ transplantation","History or consideration of left ventricular assist device (LVAD)","Life expectancy \\\u003C1 year from time of screening","Non-cardiovascular conditions interfering with 6MWT distance assessment","Inability to fulfill protocol requirements","Known allergy to silicone or titanium","Inclusion Criteria:\n\n* Diagnosis of heart failure with reduced ejection fraction (defined as ejection fraction ≤ 35% for the purposes of this study) (should be within 12 months of screen)\n* Symptoms consistent with one of:\n\n  1. current New York Heart Association (NYHA) Class III or\n  2. current NYHA Class II and historical NYHA Class III\n* Laboratories with last N-terminal pro-B-type natriuretic peptide (NT-proBNP) \\\u003C 1600 pg\u002Fml (should be within 3 months of screen)\n* Management with maximally-tolerated GDMT medications and devices\n* Age \\>= 18 years\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Myocardial infarction (MI), syncope, cerebrovascular accident (CVA), aborted sudden cardiac death (SCD) (and implantable cardioverter defibrillator (ICD) therapy) within 3 months of screening\n* Bilateral carotid bifurcations located above the level of the mandible\n* Carotid artery stenosis greater than 50% caused by atherosclerosis\n* Ulcerative plaques in the carotid artery\n* Baroreflex failure or autonomic neuropathy\n* Symptomatic un-controlled bradyarrhythmias\n* Severe chronic lung disease\n* Current treatment with inotropes\n* Pacemaker or ICD within 3 months of screening\n* Cardiac resynchronization therapy (CRT) devices within 6 months of screening or anticipated to be placed in the next 90 days following screening\n* Prior surgery, radiation, endovascular stent in the carotid sinus\n* History or consideration of solid organ transplantation\n* History or consideration of left ventricular assist device (LVAD)\n* Life expectancy \\\u003C1 year from time of screening\n* Non-cardiovascular conditions interfering with 6MWT distance assessment\n* Inability to fulfill protocol requirements\n* Known allergy to silicone or titanium",[135,136],"ADULT","OLDER_ADULT",[138,156,172,188,201,212,222],{"facility":139,"status":140,"city":141,"state":142,"zip":143,"country":144,"contacts":145,"geoPoint":153},"University of California San Francisco Health","NOT_YET_RECRUITING","San Francisco","California","94143","United States",[146,151],{"name":147,"role":148,"phone":149,"email":150},"Liviu Klein, MD","CONTACT","415-353-2873","liviu.klein@ucsf.edu",{"name":147,"role":152},"PRINCIPAL_INVESTIGATOR",{"lat":154,"lon":155},37.77493,-122.41942,{"facility":157,"status":140,"city":158,"state":159,"zip":160,"country":144,"contacts":161,"geoPoint":169},"MedStar Health","Washington D.C.","District of Columbia","20010",[162,166,167],{"name":163,"role":148,"phone":164,"email":165},"Farooq H. Sheikh, MD","202-877-4698","farooq.h.sheikh@medstar.net",{"name":163,"role":152},{"name":168,"role":152},"Richa Gupta, MD",{"lat":170,"lon":171},38.89511,-77.03637,{"facility":173,"status":140,"city":174,"state":175,"zip":176,"country":144,"contacts":177,"geoPoint":185},"University of Chicago Medical Center","Chicago","Illinois","15212",[178,182,183],{"name":179,"role":148,"phone":180,"email":181},"Manreet Kanwar, MD","773-702-9461","manreetkanwar@uchicago.edu",{"name":179,"role":152},{"name":184,"role":152},"Mark Belkin, MD",{"lat":186,"lon":187},41.85003,-87.65005,{"facility":189,"status":140,"city":190,"state":190,"zip":191,"country":144,"contacts":192,"geoPoint":198},"Weill Cornell Medicine","New York","10021",[193,197],{"name":194,"role":148,"phone":195,"email":196},"Maria Karas, MD","646-962-5555","mgk2002@med.cornell.edu",{"name":194,"role":152},{"lat":199,"lon":200},40.71427,-74.00597,{"facility":202,"status":8,"city":190,"state":190,"zip":203,"country":144,"contacts":204,"geoPoint":211},"Columbia University Irving Medical Center","10032",[205,209],{"name":206,"role":148,"phone":207,"email":208},"Gabriel T. Sayer, MD","212-342-3259","gts2102@cumc.columbia.edu",{"name":210,"role":152},"Nir Uriel, MD",{"lat":199,"lon":200},{"facility":213,"status":140,"city":190,"state":190,"zip":214,"country":144,"contacts":215,"geoPoint":221},"Montefiore Medical Center","10461",[216,220],{"name":217,"role":148,"phone":218,"email":219},"Ulrich P. Jorde, MD","718-920-2626","ujorde@montefiore.org",{"name":217,"role":152},{"lat":199,"lon":200},{"facility":223,"status":140,"city":224,"state":225,"zip":226,"country":144,"contacts":227,"geoPoint":233},"Medical University of South Carolina Health","Charleston","South Carolina","29425",[228,232],{"name":229,"role":148,"phone":230,"email":231},"Ryan J. Tedford, MD","843-792-1952","tedfordr@musc.edu",{"name":229,"role":152},{"lat":234,"lon":235},32.77632,-79.93275,[237],{"name":238,"role":148,"phone":239,"email":240},"Morgan Smith, MD","914-629-3121","mds2225@cumc.columbia.edu",[242],{"name":210,"affiliation":13,"role":152},[244,248],{"pmid":245,"type":246,"citation":247},"32616150","BACKGROUND","Zile MR, Lindenfeld J, Weaver FA, Zannad F, Galle E, Rogers T, Abraham WT. Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2020 Jul 7;76(1):1-13. doi: 10.1016\u002Fj.jacc.2020.05.015.",{"pmid":249,"type":246,"citation":250},"35713888","Coats AJS, Abraham WT, Zile MR, Lindenfeld JA, Weaver FA, Fudim M, Bauersachs J, Duval S, Galle E, Zannad F. Baroreflex activation therapy with the Barostim device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials. Eur J Heart Fail. 2022 Sep;24(9):1665-1673. doi: 10.1002\u002Fejhf.2573. Epub 2022 Jul 3.",[252],{"label":253,"url":254},"Summary of Safety and Effectiveness Data (SSED; FDA)","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcdrh_docs\u002Fpdf18\u002FP180050b.pdf",{"nct_id":4,"conditions":256,"biomarkers":258},[257],"Heart Failure",[],{"nct_id":4,"found":260,"summary":261,"prompt_version":271},true,{"design":262,"status":263,"heading":264,"summary":265,"follow_up":266,"word_count":267,"commitments":268,"compensation":269,"drugs_mentioned":270},"This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 58 participants.","completed","Barostimulation for Heart Failure with Reduced Ejection Fraction (HFrEF)","This study is looking at how a device called Barostim™ (made by CVRx Inc.) helps adults with heart failure with reduced ejection fraction (HFrEF). HFrEF means your heart can't pump enough blood to your body. The Barostim™ device is already approved by the FDA and works by stimulating nerves to improve heart function. You might be able to join if you have HFrEF with an ejection fraction of 35% or less, and still have symptoms despite taking all your heart medications. The study wants to see how this device affects blood flow and pressures in your heart during exercise. Success would mean a change in your peak exercise PCWP (a measure of heart pressure) after 6 months. The current status of this study is unclear, and it plans to enroll 58 participants.","The primary endpoint is measured at approximately 6 months after the device titration is complete, which is about 7-9 months after implantation.",132,"You would have the Barostim™ device implanted and adjusted. Your heart function, symptoms, and exercise ability would be assessed, including measurements of heart pressures during exercise.","Not stated in the trial record.",[],"v2"]